nach oben

Drugs & Aging

Erschienen in:

05.07.2021 | Review Article

Diagnosis and Management of Pain in Parkinson's Disease: A New Approach

verfasst von: Veit Mylius, Jens Carsten Möller, Stephan Bohlhalter, Daniel Ciampi de Andrade, Santiago Perez Lloret

Erschienen in: Drugs & Aging | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Pain is a frequent and disabling non-motor feature of Parkinson’s disease (PD). The recently proposed PD Pain Classification System (PD-PCS) allows for an association of pain with PD to be determined before being allocated to the main pain mechanism (i.e. nociceptive, neuropathic, and nociplastic). In this article, previous studies on treatments for pain in PD are summarized according to the pain mechanisms. A mechanistic approach to treatment is discussed. We suggest that the first step should be optimizing dopaminergic therapy before other therapy is started. When these treatments remain unsuccessful, further causes of pain must be considered. The role of drugs, invasive treatments, and physiotherapeutic interventions are discussed with a focus on older PD patients and considering polypharmacy, altered pharmacokinetics, and comorbidities.

Lubomski M, Davis RL, Sue CM. Health-related quality of life for Parkinson’s disease patients and their caregivers. J Mov Disord. 2021;14(1):42–52.PubMedPubMedCentralCrossRef

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(8):509.PubMedCrossRef

Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manage. 2006;32(5):462–9.PubMedCrossRef

Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, et al. The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain. 2021;162(4):1201–10.PubMedCrossRef

Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice AS, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382–6.PubMedCrossRef

Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19–27.PubMedCrossRef

Klietz M, Greten S, Wegner F, Hoglinger GU. Safety and tolerability of pharmacotherapies for Parkinson’s disease in geriatric patients. Drugs Aging. 2019;36(6):511–30.PubMedCrossRef

Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60.PubMedCrossRef

Katzen HL, Levin BE, Weiner W. Side and type of motor symptom influence cognition in Parkinson’s disease. Mov Disord. 2006;21(11):1947–53.PubMedCrossRef

10.

Ghosh P, Imbriani P, Caputi N, Natoli S, Schirinzi T, Di Lazzaro G, et al. A dual centre study of pain in Parkinson’s disease and its relationship with other non-motor symptoms. J Parkinsons Dis. 2020;10(4):1817–25.PubMedCrossRef

11.

Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):S41–6.PubMedCrossRef

12.

Low V, Ben-Shlomo Y, Coward E, Fletcher S, Walker R, Clarke CE. Measuring the burden and mortality of hospitalisation in Parkinson’s disease: a cross-sectional analysis of the English Hospital Episodes Statistics database 2009–2013. Parkinsonism Relat Disord. 2015;21(5):449–54.PubMedCrossRef

13.

Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25(11):1646–51.PubMedCrossRef

14.

Suttrup I, Warnecke T. Dysphagia in Parkinson’s disease. Dysphagia. 2016;31(1):24–32.PubMedCrossRef

15.

McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126.PubMedPubMedCentralCrossRef

16.

Klietz M, Tulke A, Muschen LH, Paracka L, Schrader C, Dressler DW, et al. Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson’s disease patients. Front Neurol. 2018;9:120.PubMedPubMedCentralCrossRef

17.

Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65(9):1191–4.PubMedCrossRef

18.

Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson’s disease: prevalence and characteristics. Pain. 2009;141(1–2):173–7.PubMedCrossRef

19.

Martinez-Martin P, Manuel Rojo-Abuin J, Rizos A, Rodriguez-Blazquez C, Trenkwalder C, Perkins L, et al. Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale. NPJ Parkinsons Dis. 2017;3:8.PubMedPubMedCentralCrossRef

20.

Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–6.PubMedPubMedCentralCrossRef

21.

Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62(12):2171–5.PubMedCrossRef

22.

Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78(10):1140–2.PubMedPubMedCentralCrossRef

23.

Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, Moller JC. Pain sensitivity and clinical progression in Parkinson’s disease. Mov Disord. 2011;26(12):2220–5.PubMedCrossRef

24.

Mylius V, Engau I, Teepker M, Stiasny-Kolster K, Schepelmann K, Oertel WH, et al. Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(1):24–8.PubMedCrossRef

25.

Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson’s disease? Mov Disord. 2008;23(12):1689–95.PubMedCrossRef

26.

Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20(12):1557–63.PubMedCrossRef

27.

Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive brain activation in patients with neuropathic pain related to Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(5):548–52.PubMedCrossRef

28.

Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, et al. Dopaminergic denervation using [(123)I]-FPCIT and pain in Parkinson’s disease: a correlation study. J Neural Transm (Vienna). 2019;126(3):279–87.CrossRef

29.

Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007;113(4):421–9.PubMedCrossRef

30.

Nolano M, Provitera V, Estraneo A, Selim MM, Caporaso G, Stancanelli A, et al. Sensory deficit in Parkinson’s disease: evidence of a cutaneous denervation. Brain. 2008;131(Pt 7):1903–11.PubMedCrossRef

31.

Mylius V, Kunz M, Hennighausen E, Lautenbacher S, Schepelmann K. Effects of ageing on spinal motor and autonomic pain responses. Neurosci Lett. 2008;446(2–3):129–32.PubMedCrossRef

32.

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.PubMedCrossRef

33.

Chaudhuri KR, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Mamikonyan E, et al. The movement disorder society nonmotor rating scale: initial validation study. Mov Disord. 2020;35(1):116–33.PubMedCrossRef

34.

Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75–81.PubMedCrossRef

35.

Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901–11.PubMedCrossRef

36.

Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–23.PubMedCrossRef

37.

Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, et al. How to diagnose parkinsonian central pain? Parkinsonism Relat Disord. 2019;64:50–3.PubMedCrossRef

38.

Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson’s disease. Lancet. 1986;1(8494):1366–9.PubMedCrossRef

39.

Wasner G, Deuschl G. Pains in Parkinson disease–many syndromes under one umbrella. Nat Rev Neurol. 2012;8(5):284–94.PubMedCrossRef

40.

Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, et al. Pain in Parkinson’s disease: current concepts and a new diagnostic algorithm. Mov Disord Clin Pract. 2015;2(4):357–64.PubMedPubMedCentralCrossRef

41.

Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1–2):29–36.PubMedCrossRef

42.

Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, et al. King’s Parkinson’s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623–31.PubMedCrossRef

43.

Martinez-Martin P, Rizos AM, Wetmore J, Antonini A, Odin P, Pal S, et al. First comprehensive tool for screening pain in Parkinson’s disease: the King’s Parkinson’s Disease Pain Questionnaire. Eur J Neurol. 2018;25(10):1255–61.PubMedCrossRef

44.

Perez-Lloret S, Ciampide Andrade D, Lyons KE, Rodriguez-Blazquez C, Chaudhuri KR, Deuschl G, et al. Rating scales for pain in Parkinson’s disease: critique and recommendations. Mov Disord Clin Pract. 2016;3(6):527–37.PubMedPubMedCentralCrossRef

45.

Kunz M, Mylius V, Scharmann S, Schepelman K, Lautenbacher S. Influence of dementia on multiple components of pain. Eur J Pain. 2009;13(3):317–25.PubMedCrossRef

46.

Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.PubMedCrossRef

47.

Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol (Paris). 2019;175(1–2):16–25.PubMedCrossRef

48.

Terminology of The International Association for the Study of Pain (IASP). 2021. https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698-Nociplasticpain

49.

Sa KN, Moreira L, Baptista AF, Yeng LT, Teixeira MJ, Galhardoni R, et al. Prevalence of chronic pain in developing countries: systematic review and meta-analysis. Pain Rep. 2019;4(6):e779.PubMedCrossRef

50.

Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;68(1):28–36.PubMedCrossRef

51.

Hinz A, Brahler E. Normative values for the hospital anxiety and depression scale (HADS) in the general German population. J Psychosom Res. 2011;71(2):74–8.PubMedCrossRef

52.

Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.PubMedCrossRef

53.

Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9–15.PubMedCrossRef

54.

Ehrt U, Larsen JP, Aarsland D. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry. 2009;17(4):269–75.PubMedCrossRef

55.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.PubMedPubMedCentralCrossRef

56.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Valis M, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14(12):1161–70.PubMedCrossRef

57.

Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, et al. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson’s disease-associated chronic pain. J Clin Pharmacol. 2016;56(7):852–61.PubMedCrossRef

58.

Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord. 2009;24(8):1233–7.PubMedCrossRef

59.

Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):57–61.PubMedCrossRef

60.

Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22(10):1400–7.PubMedCrossRef

61.

Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9.PubMedCrossRef

62.

Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;6(14):42.CrossRef

63.

Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–80.PubMedCrossRef

64.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61(10):1563–8.PubMedCrossRef

65.

Muller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56(3):251–61.PubMedCrossRef

66.

Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–37.PubMedCrossRef

67.

Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of safinamide on pain in fluctuating Parkinson’s disease patients: a post-hoc analysis. J Parkinsons Dis. 2017;7(1):95–101.PubMedPubMedCentralCrossRef

68.

Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29(10):1273–80.PubMedCrossRef

69.

Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson’s disease chronic pain. Adv Ther. 2018;35(4):515–22.PubMedPubMedCentralCrossRef

70.

Geroin C, Di Vico IA, Squintani G, Segatti A, Bovi T, Tinazzi M. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: an exploratory study. J Neural Transm (Vienna). 2020;127(8):1143–52.CrossRef

71.

Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, Kagi G, Raw J, et al. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial. J Parkinsons Dis. 2021;11(1):187–98.PubMedPubMedCentralCrossRef

72.

Kumagai T, Nagayama H, Ota T, Nishiyama Y, Mishina M, Ueda M. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2014;37(6):173–6.PubMedCrossRef

73.

Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(8):815–8.PubMedCrossRef

74.

Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson’s disease. J Neurol Sci. 2012;319(1–2):86–8.PubMedCrossRef

75.

Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trials. Drug Saf. 2010;33(2):147–61.PubMedCrossRef

76.

Miyasaki JM. Evidence-based initiation of dopaminergic therapy in Parkinson’s disease. J Neurol. 2010;257(Suppl 2):S309–13.PubMedCrossRef

77.

Knop J, Hoier E, Ebner T, Fromm MF, Muller F. Renal tubular secretion of pramipexole. Eur J Pharm Sci. 2015;15(79):73–8.CrossRef

78.

Cawello W, Fichtner A, Boekens H, Braun M. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur J Drug Metab Pharmacokinet. 2014;39(3):155–63.PubMedCrossRef

79.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.PubMedCrossRef

80.

Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20(4):277–81.PubMedPubMedCentralCrossRef

81.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154–65.PubMedCrossRef

82.

Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets. 2017;16(4):425–39.PubMedCrossRef

83.

Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J, investigators Ss. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014;34(12):1250–8.PubMedCrossRef

84.

Anttila M, Sotaniemi EA, Pelkonen O, Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther. 2005;77(1):54–62.PubMedCrossRef

85.

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32(12):1701–9.PubMedPubMedCentralCrossRef

86.

Schwartz M, Patel M, Kazzi Z, Morgan B. Cardiotoxicity after massive amantadine overdose. J Med Toxicol. 2008;4(3):173–9.PubMedPubMedCentralCrossRef

87.

Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30(4):201–5.PubMedCrossRef

88.

Iwaki H, Ando R, Tada S, Nishikawa N, Tsujii T, Yamanishi Y, et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson’s disease. J Neurol Sci. 2020;414:116833.PubMedCrossRef

89.

Buhmann C, Wrobel N, Grashorn W, Fruendt O, Wesemann K, Diedrich S, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. J Neurol. 2017;264(4):758–69.PubMedCrossRef

90.

Freo U, Furnari M, Ori C. Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson’s disease. J Pain Res. 2018;11:1849–56.PubMedPubMedCentralCrossRef

91.

Shohet A, Khlebtovsky A, Roizen N, Roditi Y, Djaldetti R. Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease. Eur J Pain. 2017;21(3):486–93.PubMedCrossRef

92.

Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, et al. Medical Cannabis in Parkinson disease: real-life patients’ experience. Clin Neuropharmacol. 2017;40(6):268–72.PubMedCrossRef

93.

Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014;37(2):41–4.PubMedCrossRef

94.

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088–98.PubMedCrossRef

95.

Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245–50.PubMedCrossRef

96.

Yenilmez F, Frundt O, Hidding U, Buhmann C. Cannabis in Parkinson’s disease: the patients’ view. J Parkinsons Dis. 2021;11(1):309–21.PubMedCrossRef

97.

Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, et al. Incobotulinum toxin A in Parkinson’s disease with foot dystonia: a double blind randomized trial. Parkinsonism Relat Disord. 2018;46:9–15.PubMedCrossRef

98.

Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH. Botulinum toxin type A for pain in advanced Parkinson’s disease. Can J Neurol Sci. 2018;45(1):23–9.PubMedCrossRef

99.

Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1–2):109–18.PubMedCrossRef

100.

Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(12):2361–72.PubMedCrossRef

101.

Marcum ZA, Duncan NA, Makris UE. Pharmacotherapies in geriatric chronic pain management. Clin Geriatr Med. 2016;32(4):705–24.PubMedPubMedCentralCrossRef

102.

Wehling M. How to use the FORTA (“Fit fOR The Aged”) list to improve pharmacotherapy in the elderly. Drug Res (Stuttg). 2016;66(2):57–62.PubMed

103.

Wehling M. Forta—Fit for the Aged. 2021. https://www.umm.uni-heidelberg.de/klinische-pharmakologie/forschung/forta-projekt/. Accessed Mar 2021.

104.

Greten S, Muller-Funogea JI, Wegner F, Hoglinger GU, Simon N, Junius-Walker U, et al. Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna). 2021;128(1):49–60.CrossRef

105.

Krack P, Volkmann J, Tinkhauser G, Deuschl G. Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord. 2019;34(12):1795–810.PubMedCrossRef

106.

Cury RG, Galhardoni R, Fonoff ET, Dos Santos Ghilardi MG, Fonoff F, Arnaut D, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology. 2014;83(16):1403–9.PubMedCrossRef

107.

Cury RG, Galhardoni R, Fonoff ET, Perez Lloret S, Dos Santos Ghilardi MG, Barbosa ER, et al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2016;20(2):151–65.PubMedCrossRef

108.

Cury RG, Galhardoni R, Teixeira MJ, Dos Santos Ghilardi MG, Silva V, Myczkowski ML, et al. Subthalamic deep brain stimulation modulates conscious perception of sensory function in Parkinson’s disease. Pain. 2016;157(12):2758–65.PubMedCrossRef

109.

Cury RG, Teixeira MJ, Galhardoni R, Silva V, Iglesio R, Franca C, et al. Connectivity patterns of subthalamic stimulation influence pain outcomes in Parkinson’s disease. Front Neurol. 2020;11:9.PubMedPubMedCentralCrossRef

110.

Othman AA, Rosebraugh M, Chatamra K, Locke C, Dutta S. Levodopa-carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa-carbidopa. J Parkinsons Dis. 2017;7(2):275–8.PubMedPubMedCentralCrossRef

111.

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.PubMedCrossRef

112.

Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13–20.PubMedCrossRef

113.

Buongiorno M, Antonelli F, Camara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015;21(8):871–6.PubMedCrossRef

114.

Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, investigators Gs, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231–5.PubMedCrossRef

115.

Morgante F, Oppo V, Fabbri M, Olivola E, Sorbera C, De Micco R, et al. Levodopa-carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age. J Neurol. 2020;268:1728–37.PubMedPubMedCentralCrossRef

116.

Nguy V, Barry BK, Moloney N, Hassett LM, Canning CG, Lewis SJG, et al. Exercise-induced hypoalgesia is present in people with Parkinson’s disease: two observational cross-sectional studies. Eur J Pain. 2019;23(7):1329–39.PubMed

117.

Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson’s disease. J Aging Res. 2011;2011:232473.PubMedPubMedCentralCrossRef

Titel: Diagnosis and Management of Pain in Parkinson's Disease: A New Approach
verfasst von: Veit Mylius
Jens Carsten Möller
Stephan Bohlhalter
Daniel Ciampi de Andrade
Santiago Perez Lloret
Publikationsdatum: 05.07.2021
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 7/2021
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-021-00867-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Correction to: A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019)

Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia

Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice

Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity

Drug–Drug Interactions in Patients with COVID-19 in Nursing Homes